围手术期红细胞输注与全髋及全膝关节置换术后症状性静脉血栓栓塞症的关联
该回顾性研究纳入2001至2016年单中心29003例初次全髋或全膝关节置换术患者,2500例(8.62%)接受围手术期红细胞输注,302例(1.04%)在术后90天内发生症状性静脉血栓栓塞症。单因素分析显示红细胞输注与静脉血栓栓塞症风险轻度升高相关(OR 1.53,95%CI 1.09-2.16),但经多因素分析(OR 0.42,95%CI 0.12-1.39)和倾向性评分匹配(OR 1.2,95%CI 0.7-1.8)调整后该差异消失。作者结论认为,调整宿主静脉血栓栓塞症风险评分及其他混杂因素后,围手术期红细胞输注未显著增加初次全髋及全膝关节置换术后90天内症状性静脉血栓栓塞症的发生率。
要点
- 29003例初次全髋或全膝关节置换术中,2500例(8.62%)接受围手术期红细胞输注,302例(1.04%)术后90天内发生症状性静脉血栓栓塞症。
- 单因素分析显示红细胞输注与静脉血栓栓塞症风险轻度升高相关(OR 1.53,95%CI 1.09-2.16)。
- 多因素分析(OR 0.42,95%CI 0.12-1.39)和倾向性评分匹配(OR 1.2,95%CI 0.7-1.8)后,红细胞输注与静脉血栓栓塞症的关联不再显著。
核心结论
- 调整宿主静脉血栓栓塞症风险评分及其他混杂因素后,围手术期红细胞输注未显著增加初次全髋及全膝关节置换术后90天内症状性静脉血栓栓塞症的发生率。
- 作者认为,在有指征的情况下,全髋及全膝关节置换术后可安全地进行围手术期红细胞输注。
研究设计与样本
- 回顾性研究,纳入2001年至2016年单中心所有接受初次全髋或全膝关节置换术的患者。
主要发现
- 在29003例接受全髋或全膝关节置换术的患者中,2500例(8.62%)接受围手术期红细胞输注,302例(1.04%)在术后90天内发生症状性静脉血栓栓塞症。
- 单因素分析显示红细胞输注与静脉血栓栓塞症风险轻度升高相关(OR 1.53,95%CI 1.09-2.16)。
- 多因素分析显示红细胞输注与静脉血栓栓塞症的关联无统计学显著性(OR 0.42,95%CI 0.12-1.39)。
- 基于患者合并症的倾向性评分匹配分析显示红细胞输注与静脉血栓栓塞症的关联无统计学显著性(OR 1.2,95%CI 0.7-1.8)。
临床怎么用
- 作者认为,在有指征的情况下,全髋及全膝关节置换术后可安全地进行围手术期红细胞输注。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prior registry data suggest that perioperative red blood cell (RBC) transfusion may increase the incidence of venous thromboembolism (VTE) in patients status post surgery. However, there are limited data that explore VTE risk after perioperative transfusion in the setting of primary total joint arthroplasty (TJA). Our aim is to investigate the association between perioperative RBC transfusion and the development of symptomatic VTE after adjusting for confounding variables. METHODS: We retrospectively reviewed all patients undergoing primary TJA at a single institution from 2001 to 2016. The primary outcome was development of symptomatic VTE (deep vein thrombosis or pulmonary embolism) up to 90 days following primary TJA. To identify the association between RBC transfusion and development of VTE, univariate and multivariate analyses were used, as well as a sensitivity analysis using propensity score matching based on patient comorbidities. RESULTS: Of the 29,003 patients who underwent TJA, 2500 (8.62%) received RBC transfusion perioperatively and 302 (1.04%) developed a postoperative VTE within 90 days of surgery. While univariate analysis did suggest a slightly increased incidence of VTE in association with RBC transfusion (odds ratio [OR], 1.53; 95% confidence interval [CI], 1.09-2.16), this difference was eliminated when multivariate analysis (OR, 0.42; 95% CI, 0.12-1.39) and propensity score matching (propensity-matched OR, 1.2; 95% CI, 0.7-1.8) were employed. CONCLUSION: Perioperative RBC transfusion does not significantly increase the incidence of symptomatic VTE following primary TJA in the 90-day postoperative period after adjustment for host VTE risk scores and other confounding variables. Perioperative RBC transfusion may be safely administered if indicated following total hip and knee arthroplasty.
引用
- Jackson A, Goswami K, Yayac M, et al. Association of Perioperative Red Blood Cell Transfusion With Symptomatic Venous Thromboembolism Following Total Hip and Knee Arthroplasty. J Arthroplasty. 2020. PMID: 32771288. doi:10.1016/j.arth.2020.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。